tga bpc 157 approval status Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel | 3 Biotech TGA cracks down on unregulated
Description
The GAG composition is altered, reducing hydration and resilience
The new frontier
Phase II clinical trials for inflammatory bowel disease reported no toxicity or adverse events in treated patients, though detailed safety data from these trials have not been published in peer-reviewed literature
Seckinger, P., Isaaz, S
859 However, it remains unclear as yet why nitrile hydratase activation requires a specific metallochaperone, and molecular details of cofactor biogenesis remain largely lacking
